Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).

Financial Outlook

Based on current operating plans, the Company expects that its existing cash, cash equivalents and marketable securities will fund its research and development programs and other operations through the first quarter of 2017.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.